Skip to main content

29-04-2020 | Oncology | News | Article

AACR 2020 in brief

EMBRACA: Final OS analysis fails to show talazoparib benefit

Author: Lynda Williams

medwireNews: Talazoparib does not extend overall survival (OS) compared with a physician’s choice of chemotherapy, shows the EMBRACA trial of HER2-negative locally advanced and metastatic breast cancer patients with a germline (g)BRCA1/2 mutation.

Previously the primary endpoint of progression-free survival in the phase 3 study found a significant benefit with talazoparib 1 mg/day versus capecitabine, eribulin, gemcitabine, or vinorelbine.

But the latest findings for the secondary endpoint of OS show no significant difference between the talazoparib and chemotherapy treatment arms, at a median duration of 19.3 and 19.5 months, respectively, reported Jennifer Litton (The University of Texas MD Anderson Cancer Center, Houston, USA) at the 2020 AACR Virtual Annual Meeting I.

Nevertheless, talazoparib was “generally well tolerated with manageable toxicity,” the presenting author said, with comparable rates of grade 3–4 serious adverse events to chemotherapy (28.3 vs 27.0%) and similar rates of permanent discontinuation due to adverse events (7.7 vs 9.5%).

And talazoparib significantly delayed the time to clinically meaningful deterioration based on global health status/quality of life versus chemotherapy, prompting Litton to conclude that the PARP inhibitor “is a favorable treatment option for patients with [locally advanced] or metastatic breast cancer with a gBRCA1/2 mutation.”

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group

2020 AACR Virtual Annual Meeting I; 27–28 April